Compare PTCT & VNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | VNO |
|---|---|---|
| Founded | 1998 | 1946 |
| Country | United States | United States |
| Employees | N/A | 3145 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.3B |
| IPO Year | 2006 | N/A |
| Metric | PTCT | VNO |
|---|---|---|
| Price | $76.82 | $39.72 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 10 |
| Target Price | ★ $80.65 | $33.00 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 2.52% |
| EPS Growth | ★ 264.48 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $264,734,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.70 | $5.42 |
| P/E Ratio | ★ N/A | $7.08 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $43.18 | $24.57 |
| 52 Week High | $90.87 | $43.37 |
| Indicator | PTCT | VNO |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 58.23 |
| Support Level | $74.45 | $37.92 |
| Resistance Level | $79.67 | $41.08 |
| Average True Range (ATR) | 3.27 | 1.23 |
| MACD | -1.01 | -0.20 |
| Stochastic Oscillator | 4.47 | 63.87 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.